Outcomes of Chemoimmunotherapy Among Patients With Extensive-Stage Small Cell Lung Cancer According to Potential Clinical Trial Eligibility

IMPORTANCE: Chemoimmunotherapy is the standard first-line therapy for patients with extensive-stage small cell lung cancer (ES-SCLC). However, whether findings from pivotal trials can be extrapolated to the clinical practice setting remains unclear. OBJECTIVE: To compare treatment outcome gaps follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujimoto, Daichi, Morimoto, Takeshi, Tamiya, Motohiro, Hata, Akito, Matsumoto, Hirotaka, Nakamura, Atsushi, Yokoyama, Toshihide, Taniguchi, Yoshihiko, Uchida, Junji, Sato, Yuki, Yokoi, Takashi, Tanaka, Hisashi, Furuya, Naoki, Masuda, Takeshi, Sakata, Yoshihiko, Miyauchi, Eisaku, Hara, Satoshi, Saito, Go, Miura, Satoru, Kanazu, Masaki, Yamamoto, Nobuyuki, Akamatsu, Hiroaki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Medical Association 2023
Materias:
Original Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958526/
https://www.ncbi.nlm.nih.gov/pubmed/36826813
http://dx.doi.org/10.1001/jamanetworkopen.2023.0698

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9958526/
https://www.ncbi.nlm.nih.gov/pubmed/36826813
http://dx.doi.org/10.1001/jamanetworkopen.2023.0698

Ejemplares similares